Who We Are Caring Discovery Products Careers Investors Partners Newsroom ← WHO WE ARE | Business Areas Elanco Animal Health WHO WE ARE BUSINESS AREAS Elanco Animal Health At Elanco, we advance our vision of food and companionship enriching life by developing innovative solutions that protect and enhance animal health. Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower veterinarians, food producers and all those concerned with animal health with the tools needed to help animals live healthy lives. Our Perspective on Animal Health Healthy animals play a critical role in the health of people and our planet. Our business is based on innovative animal health solutions that contribute to healthier animals, and ultimately healthier people and a healthier environment. We believe that starting with animals is the key to solving our global health care, food security, and sustainability challenges. Elanco combines a holistic world view and decades of experience for a unique perspective in animal health, and its impact on the world. We bring this to life daily, both through the products and services we offer and the initiatives that result from our approach Jeff Simmons, President, Elanco Animal Health "At Elanco, our vision is simple: food and companionship enriching life. Over the last 60 years, we’ve been on a journey to live this vision every day by enabling veterinarians to help pets live longer, healthier lives and by making food affordable, available and sustainable." Privacy Statement Terms of Use Diversity Suppliers Login Sitemap Contact Copyright © 2018 Eli Lilly and Company. All rights reserved.

Who We Are Caring Discovery Products Careers Investors Partners Newsroom ← WHO WE ARE | Diversity & Inclusion Diversity in Clinical Trials WHO WE ARE DIVERSITY & INCLUSION Diversity in Clinical Trials Responses to medicines can vary depending on a number of factors, including someone’s genetic background, ethnicity, gender and lifestyle. This is why it’s critical for Lilly to have diverse representation in clinical trials – to gain the insights necessary to make medicines that will be the most effective for all people who use them. Unfortunately, minority populations have been historically and consistently underrepresented in clinical trials. As a result, important information about how medicines work in minority populations is not always available. In response, Lilly has developed a clinical trial diversity strategy to better understand patient differences that may affect clinical outcomes and to help increase the enrollment of racially and ethnically diverse populations in U.S. clinical trials. The ultimate goal of our clinical trial diversity strategy is to improve health outcomes for individual patients. Learn more about what to expect in clinical trials here. Lilly Employees Help Build Diversity in Clinical Trials ABOUT Training Minority Clinical Trial Investigators ABOUT Diversity in Lilly Trials ABOUT Closing the Diversity Gap in Clinical Trials ABOUT Privacy Statement Terms of Use Diversity Suppliers Login Sitemap Contact Copyright © 2018 Eli Lilly and Company. All rights reserved.